United States Patent 6,180,639: Lamivudine Combination Claims, Patent Scope, Expiry and Generic Risk

United States Patent 6,180,639 covers combinations and co-administration of the lamivudine enantiomer, chemically identified as (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, with another antiviral agent. Its principal limitations are: HIV treatment, lamivudine stereochemical purity, combination with an antiviral, and specified dose or administration formats.

The patent is expired. Its practical effect today is historical and interpretive rather than exclusionary. It does not create a current U.S. barrier to generic lamivudine, lamivudine/zidovudine products, or other antiretroviral combinations, subject to separate active patents covering a particular product, formulation, manufacturing process, or later therapeutic use.

What drug does U.S. Patent 6,180,639 protect?

The claimed compound is lamivudine, also known as 3TC. The patent identifies it by its stereochemical chemical name rather than by the later International Nonproprietary Name.

Patent element	Scope
Active compound	(-)-cis lamivudine
Opposite enantiomer	(+)-enantiomer
Purity threshold	No more than 5% of the combined (+) and (-) enantiomers
Narrower thresholds	No more than 2% or 1% of the (+)-enantiomer
Disease	HIV infection
Combination requirement	Another agent having antiviral activity
Dosage ranges	10-1,500 mg per composition; narrower claims include 20-1,000 mg and 50-700 mg
Daily dose ranges	0.1-750 mg/kg/day, narrowed to 0.5-60 mg/kg/day and 1-20 mg/kg/day
Administration	Simultaneous, sequential, or “in combination”
Product formats	Pharmaceutical compositions, combinations, and articles of manufacture

The patent does not claim lamivudine as a standalone chemical entity in the claims supplied. Its claims are directed to combination therapy and combination products.

The (-)-enantiomer limitation is central. A product containing racemic 1:1 material would not meet the express purity limitation, because the amount of the (+)-enantiomer would exceed 5%. Commercial lamivudine, however, is the therapeutically relevant (-)-enantiomer and ordinarily satisfies the stereochemical limitation.

How are the 64 claims organized?

The claims divide into five functional groups.

Claims	Claim category	Main subject
1-12	Method of treatment	Treating HIV with lamivudine plus another antiviral
13-26	Pharmaceutical composition	Lamivudine, carrier, and another antiviral
27-40	Narrower method claims	The named lamivudine compound, specified agents, doses, and purity
41-60	Further composition, method, and combination claims	Repeated limitations for lamivudine combinations
61-64	Article-of-manufacture claims	Separate amounts of lamivudine and another antiviral

The claims contain substantial repetition. Claims 18-22 and 27-40 narrow the claims to the named free compound rather than a pharmaceutically acceptable salt. Claims 23-26 and 32-35 impose the 2% and 1% enantiomer thresholds.

Claim 37 appears to duplicate claim 36. Claim 61, as reproduced, states “according to claim 61,” which is internally defective because a claim cannot ordinarily depend on itself. The supplied text also contains typographical errors such as “fist amount,” “accroding,” “extretion,” and inconsistent chemical nomenclature. Those defects should be evaluated against the issued patent text and any certificate of correction, not against an unofficial transcription.

What are the broadest independent claims?

Claim 1: HIV treatment method

Claim 1 requires:

A human suffering from HIV infection.
Administration of a pharmaceutical composition.
The (-)-cis lamivudine compound or a pharmaceutically acceptable salt.
Another antiviral agent.
A pharmaceutically acceptable carrier.
No more than 5% of the (+)-enantiomer relative to the combined enantiomer weight.

This is a combination-treatment claim. It does not require a fixed-dose tablet. Separate administration can satisfy the broader treatment concept through dependent claims 8, 9, 36, 37, and 46-48.

The claim is potentially broad as to the second antiviral because “another agent having antiviral activity” is not limited in claim 1 to a named compound. Claims 2 and 14 provide a nonexclusive list of agent classes and named examples.

Claim 13: Pharmaceutical composition

Claim 13 covers a composition containing:

lamivudine or a pharmaceutically acceptable salt;
another antiviral agent;
a pharmaceutically acceptable carrier; and
no more than 5% of the (+)-enantiomer.

Unlike the method claims, claim 13 does not require administration to an HIV-infected human. A product manufacturer, distributor, or supplier would face a composition claim only if the product itself contains both lamivudine and another antiviral in the claimed relationship.

Claim 57: Combination

Claim 57 removes the express carrier limitation and claims a combination containing lamivudine and another antiviral. This language may reach a kit or coordinated product arrangement more readily than claim 13, depending on the product structure and claim construction.

Claim 61: Article of manufacture

The article claims appear directed to a package or kit with:

a first amount containing purified lamivudine; and
a second amount containing another antiviral.

This structure is important because it can cover co-packaged products even where the two active ingredients are not compressed into a single tablet. The claim text supplied is internally inconsistent, so the enforceable scope must be determined from the official issued claim and any correction record.

What antiviral agents fall within the claimed combination?

Claim 2 and related dependent claims identify broad categories and examples:

acyclic nucleosides;
interferons;
renal excretion inhibitors;
nucleoside transport inhibitors;
2',3'-dideoxynucleosides;
immunomodulators;
erythropoietin;
ampligen;
thyomodulin;
thymopentin;
foscarnet;
ribavirin; and
inhibitors of HIV binding to CD4.

At the time of filing, these categories covered the then-developing HIV treatment field. The most commercially important historical combination was lamivudine with zidovudine, an acyclic nucleoside and a 2',3'-dideoxynucleoside. That combination became associated with Combivir, marketed by Glaxo Wellcome and later GlaxoSmithKline.

The claims are not limited to zidovudine. They can potentially reach lamivudine combined with other antiviral agents if the remaining limitations are met. The breadth is reduced by the requirement that the compound be the specified (-)-enantiomer and that the composition or first amount contain no more than 5% of the (+)-enantiomer.

What formulations are protected by Patent 6,180,639?

The patent is not a conventional tablet-formulation patent. It does not, in the supplied claims, require a particular excipient, release profile, coating, particle size, polymorph, dosage form, or manufacturing process.

Potentially relevant products include:

Product format	Potential claim relevance
Fixed-dose lamivudine plus zidovudine tablet	Claims 13, 53, 57 and related claims
Co-packaged lamivudine and another antiviral	Claims 57 and 61-64
Separate lamivudine and antiviral doses administered sequentially	Claims 8, 36 and related method claims
Separate doses administered simultaneously	Claims 9 and related method claims
Lamivudine combination with a named listed antiviral	Claims 2, 14, 19, 51, 55, 59 and 63-64
Lamivudine monotherapy	Generally outside the supplied combination claims

A lamivudine-only tablet would generally not satisfy these claims because the claims require another antiviral agent. A combination product containing only inactive excipients with lamivudine would also lack the required second antiviral.

When did U.S. Patent 6,180,639 lose exclusivity?

U.S. Patent 6,180,639 was issued on January 30, 2001, to Glaxo Group Limited. Public patent records identify the patent as expired. The patent’s operative term ended in the 2010s, with the generally reported expiration date being January 30, 2018, subject to the controlling USPTO continuity and term-adjustment record. The patent cannot now support a new U.S. infringement action against ordinary commercial activity.

The patent is distinct from:

the earlier lamivudine compound patent;
formulation patents for specific tablets;
patents covering lamivudine/zidovudine product configurations;
process patents covering synthesis or purification; and
later patents covering other antiretroviral combinations.

Expiration of Patent 6,180,639 therefore does not establish that every patent historically associated with Epivir, Combivir, or another lamivudine product expired on the same date.

What was the Orange Book status of the patent?

The FDA Orange Book lists patents associated with approved drug products when the NDA holder submits them and the statutory listing criteria are met. Patent 6,180,639 is a combination-therapy patent rather than a basic lamivudine compound patent. Its relevance to an Orange Book listing depends on whether it was submitted and accepted for a particular approved NDA product.

The commercially significant FDA products were:

Product	Active ingredients	Originator
Epivir	Lamivudine	Glaxo Wellcome, later GSK/ViiV
Combivir	Lamivudine and zidovudine	Glaxo Wellcome, later GSK/ViiV
Trizivir	Abacavir, lamivudine and zidovudine	Glaxo Wellcome, later GSK/ViiV

For generic competition, the critical Orange Book issues were historically the listed patents for the relevant NDA, their expiration dates, and Paragraph IV certifications. Once the relevant listed patents expired, an ANDA applicant no longer faced a current patent-based delay from this patent.

Current commercial risk should therefore be assessed against the live Orange Book entries for the specific reference-listed drug, not against Patent 6,180,639 in isolation. FDA, Approved Drug Products with Therapeutic Equivalence Evaluations, is the controlling source for current listing and exclusivity status.[2]

Did Paragraph IV challenges affect lamivudine products?

Lamivudine products were subject to ANDA competition after the principal compound and product patents reached the end of their terms. An ANDA applicant can certify under Paragraph IV that a listed patent is invalid, unenforceable, or not infringed. A Paragraph IV notice can trigger Hatch-Waxman litigation and, if litigation is timely filed, a 30-month stay of approval under 21 U.S.C. § 355(j)(5)(B)(iii).

For Patent 6,180,639, the commercial importance of any Paragraph IV challenge was temporary because the patent has expired. A present-day applicant does not need to defeat an expired patent to launch a product. The relevant diligence question is whether another unexpired patent remains listed for the particular reference product.

The patent’s expired status also eliminates any current 180-day exclusivity value tied solely to this patent. Paragraph IV litigation history may remain relevant to launch chronology and settlement analysis, but it does not revive the patent.

Which companies challenged or competed against the lamivudine estate?

The competitive field included multiple generic manufacturers of lamivudine and lamivudine-containing combinations. Major companies active in the broader market have included Teva, Mylan/Viatris, Aurobindo, Cipla, Hetero and other ANDA or international suppliers.

The principal originator-side companies were:

Glaxo Group Limited, the original patent owner;
Glaxo Wellcome;
GlaxoSmithKline; and
ViiV Healthcare, which later became the specialist HIV business associated with GSK and Pfizer.

The historical commercial challenge centered on generic versions of Epivir and Combivir. The patent estate did not prevent generic entry after expiry because the claims did not remain enforceable as live U.S. rights.

How strong is the patent estate?

Strengths

The patent had several features that could have created meaningful pre-expiry leverage:

It covered both treatment methods and compositions.
It captured simultaneous, sequential, and combination administration.
It used a broad “another agent having antiviral activity” formulation in independent claims.
It imposed a purity threshold consistent with commercial enantiopure lamivudine.
It included article-of-manufacture language directed to separate product amounts.
It included dose and stereochemical dependent claims that could provide fallback positions.

Weaknesses

The claim estate also had material limitations:

It required combination therapy rather than lamivudine monotherapy.
It did not claim a broad lamivudine chemical genus in the supplied claims.
It lacked detailed formulation limitations that could distinguish alternative dosage forms.
The dependent claims substantially repeat the same limitations.
The agent lists include broad and potentially indefinite categories.
The article-of-manufacture claims, as reproduced, contain apparent drafting defects.
The patent is expired.

Before expiration, a generic could have pursued several design-around or invalidity positions, including:

selling lamivudine alone;
using a product containing no second antiviral;
challenging the written description or enablement of combinations across the full scope of “another agent having antiviral activity”;
disputing whether a particular co-packaged product constituted the claimed combination;
contesting the purity measurement or enantiomer calculation; and
challenging obviousness based on known nucleoside combination therapy and known lamivudine activity.

What manufacturing and IP barriers remain?

Patent 6,180,639 does not currently create a manufacturing barrier. Practical barriers may remain in:

achieving consistent enantiomeric purity;
controlling stereochemistry during synthesis;
validating impurity specifications;
obtaining regulatory approval for the relevant dosage form;
qualifying a supplier of active pharmaceutical ingredient;
meeting combination-product stability requirements; and
complying with country-specific patent or data-exclusivity rules.

Lamivudine is a small-molecule generic product, not a biologic. Biosimilar approval pathways do not apply. A U.S. applicant would generally pursue an ANDA for a therapeutically equivalent product or, where the product configuration differs, an appropriate 505(b)(2) pathway.

How does Patent 6,180,639 compare with compound and formulation patents?

Patent type	Typical protection	Relationship to 6,180,639
Compound patent	Lamivudine molecule or stereoisomer	Broader for standalone lamivudine, but separate patent
Combination patent	Lamivudine plus another antiviral	Direct subject of 6,180,639
Formulation patent	Tablet composition, coating, release profile, excipients	More technically specific than 6,180,639
Method-of-use patent	Treatment of a disease or patient subgroup	6,180,639 includes HIV-treatment methods
Process patent	Synthesis, resolution, purification	Potential manufacturing barrier, not claimed here
Regulatory exclusivity	FDA exclusivity period	Separate from patent rights
Biosimilar patent	Biologic product or manufacturing process	Not relevant to lamivudine

What generic launch scenarios exist?

Lamivudine monotherapy

A generic lamivudine-only product does not ordinarily fall within the combination claims because it lacks another antiviral agent. The relevant risks would instead arise from the compound, formulation, process, or Orange Book patents applicable to the reference product.

Lamivudine/zidovudine fixed-dose product

A fixed-dose combination would have been the closest historical product to the asserted scope. Before expiration, the applicant would have needed to address the combination claims and any separately listed product patents. Today, Patent 6,180,639 is not a launch blocker.

Co-packaged products

A package containing lamivudine and a second antiviral could implicate the article-of-manufacture and combination claims. Because the patent is expired, this distinction is now principally relevant to historical infringement analysis.

A different antiviral combination

The broad independent language could reach combinations involving antiviral agents not expressly named in the dependent claims, but only if all other claim limitations are satisfied. Current products should be screened against live patents directed to the newer antiviral itself and its particular formulation.

Key Takeaways

U.S. Patent 6,180,639 covers lamivudine combination therapy, not ordinary lamivudine monotherapy.
The core limitations are HIV treatment, the (-)-lamivudine enantiomer, another antiviral, and no more than 5% of the (+)-enantiomer.
Dependent claims narrow the scope to 1% or 2% enantiomer content, specified dose ranges, named antiviral classes, and administration formats.
The patent includes method, composition, combination, and article-of-manufacture claims.
The patent expired, with January 30, 2018 generally reported as the end of its enforceable term.
It does not create a current U.S. generic launch barrier.
Lamivudine-only products generally fall outside the supplied combination claims.
Current diligence should focus on the Orange Book entries and active patents for the specific reference-listed product.
Biosimilar risk is not applicable because lamivudine is a small-molecule drug.
The claim transcription contains apparent dependency and typographical defects that should be compared with the official issued patent record.

Frequently Asked Questions

Does Patent 6,180,639 cover Epivir alone?

Generally no. The supplied claims require lamivudine together with another antiviral agent. A lamivudine-only product would ordinarily require analysis under separate compound, formulation, process, or product patents.

Does the patent cover Combivir?

Combivir contains lamivudine and zidovudine, making it the principal historical product associated with the claimed combination concept. Patent 6,180,639 is expired, so it does not currently block a Combivir-type generic product.

Is lamivudine a biologic requiring a biosimilar application?

No. Lamivudine is a small-molecule nucleoside reverse transcriptase inhibitor. Generic applicants ordinarily use the ANDA pathway rather than the biosimilar pathway.

Can a product avoid the patent by using racemic lamivudine?

A racemic product would not satisfy the express no-more-than-5% (+)-enantiomer limitation. It could, however, face separate regulatory and safety issues and would not necessarily be an acceptable therapeutic substitute for commercial lamivudine.

Does expiration of this patent eliminate all lamivudine patent risk?

No. It eliminates the current enforceability of this patent. Separate patents may have covered the lamivudine compound, tablet formulation, fixed-dose combination, manufacturing process, or a later use. Those rights must be reviewed separately.

References

United States Patent and Trademark Office. (2001). U.S. Patent No. 6,180,639, Pharmaceutical compositions containing (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
21 U.S.C. § 355(j). Abbreviated applications for new drugs.
35 U.S.C. § 154. Contents and term of patent; provisional rights.
U.S. Food and Drug Administration. (1995). Epivir lamivudine prescribing information.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9009861	May 02, 1990

PCT Information
PCT Filed	May 02, 1991	PCT Application Number:	PCT/GB91/00706
PCT Publication Date:	November 14, 1991	PCT Publication Number:	WO91/17159

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	182	⤷ Start Trial
African Regional IP Organization (ARIPO)	9100255	⤷ Start Trial
Australia	651345	⤷ Start Trial
Australia	7771991	⤷ Start Trial
Bosnia and Herzegovina	96098	⤷ Start Trial
Bulgaria	60679	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,180,639

Summary for Patent: 6,180,639